Clinical Trials
Phase 3 Trial Shows REGEN-COV antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Regeneron Pharmaceuticals, Inc. announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive Phase 3 outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing...
Clinical Trials
BioAge Initiates Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Immune Aging
BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target aging to treat severe diseases, announced that it has commenced a Phase 2 clinical trial of BGE-175, a potent oral inhibitor of prostaglandin D2(PGD2) DP1 signaling with a...
News
Plus Therapeutics, Piramal Ink Master Services Agreement
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, announced that it has entered into a master services agreement (MSA) with Piramal Pharma Solutions (PPS) for the development, manufacture, and...
News
ICPA Health Products Ltd Pledges Support Towards India’s Largest Vaccination Drive
ICPA Health Products Ltd (ICPA), India’s leading pharma company in the oral healthcare segment, as part of its CSR activity has donated a sum of Rs.21 lakhs to the PM CARES Fund towards the COVID19 pandemic relief. With India...
News
Glenmark Pharma receives US FDA approval for generic Cardizem SR capsules
Glenmark Pharmaceuticals has received final approval by the United States FDA for diltiazem hydrochloride extended-release capsules USP, 60 mg, 90 mg, and 120 mg. This is the generic version of Cardizem SR extended-release capsules, 60 mg, 90 mg, and...
News
Eisai Begins Construction of Its New Injection/Research building at Kawashima Industrial Park in Japan
Eisai Co., Ltd. announced that, as part of one strategic investment towards the realization of its medium-term business plan “EWAY2025”, it has conducted the groundbreaking ceremony for the construction of a new injection/research building “Eisai Medicine Innovation Technology Solutions”...
News
Rentschler Biopharma and Leukocare extend service offering with joint U.S. site
Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Leukocare AG, a German biotechnology company specialized in the field of biopharmaceutical formulation development, celebrate the fourth anniversary of their unique strategic alliance. Established...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















